person · Reporting owner

FOLETTA MARK G

Disclosed activity across 5 companies

Tapewire entity: 26831
SEC CIK: 0001236389

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMN HEALTHCARE SERVICES INCAMN · Entity 4780	Director	June 15, 2026	June 17, 2026
DEXCOM INCDXCM · Entity 3114	Director	July 31, 2026	August 04, 2026
ENANTA PHARMACEUTICALS INCENTA · Entity 5673	Director	March 11, 2026	March 13, 2026
Forte Biosciences, Inc.TOCA · Entity 9529	EVP & Chief Financial Officer	October 04, 2019	October 05, 2019
Regulus Therapeutics Inc.RGLS · Entity 78034	Director	December 04, 2017	December 07, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMN HEALTHCARE SERVICES INC

Report date June 15, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Trust	17,917	Last balance in matching sequence After 2026-06-15 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-06-15 · Sale · Disposed 1,681 · Balance 19,917 F1: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F2: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Row 2 · 2026-06-15 · Sale · Disposed 2,000 · Balance 17,917 F4: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F5: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan").

F2: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F4: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan").

F5: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

DEXCOM INC

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Trust	48,852	Last balance in matching sequence After 2026-08-03 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-07-31 · Sale · Disposed 2,000 · Balance 50,852 F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Row 2 · 2026-08-03 · Sale · Disposed 2,000 · Balance 48,852 F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
Common StockSEC Table I · non-derivative	Direct	6,331	Reported balance Holding disclosure · report date 2026-07-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 6,331 F3: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F3: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

ENANTA PHARMACEUTICALS INC

Report date March 11, 2026 · Filed March 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11	Direct	20,000	Reported balance After 2026-03-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

Forte Biosciences, Inc.

Report date October 04, 2019 · Filed October 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03	Direct	30,000	Reported balance After 2019-10-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-10-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.

Regulus Therapeutics Inc.

Report date December 04, 2017 · Filed December 07, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	81,910	Reported balance After 2017-12-04 transaction · row 1 1 source row Row 1 · 2017-12-04 · Grant · Acquired 71,910 · Balance 81,910 F1: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 19, 2022 Filed May 23, 2022 21:05 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	1,054	$0.00	$0.00	Disclosure SEC source: 0001093557-22-000117 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,651 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
May 19, 2022 Filed May 23, 2022 21:05 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	1,054	$0.00	$0.00	Disclosure SEC source: 0001093557-22-000117 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document
April 21, 2022 Filed Apr 22, 2022 22:24 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	GrantRestricted Stock Units · Derivative	1,458	$0.00	$0.00	Disclosure SEC source: 0001209191-22-025451 · doc4.xml · derivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 Underlying: Common Stock · 1,458 shares Expires not disclosed F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F5 · derivative.exercise_date: The RSUs identified in this row were granted on April 21, 2022 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2023. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 21, 2022 Filed Apr 22, 2022 22:24 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionRestricted Stock Units · Derivative	2,139	$0.00	$0.00	Disclosure SEC source: 0001209191-22-025451 · doc4.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F3 · derivative.exercise_date: The RSUs identified in this row were granted on April 21, 2021 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2022, which will be held on May 6, 2022. Accordingly, the number of RSUs identified in this row vested on April 21, 2022. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 21, 2022 Filed Apr 22, 2022 22:24 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionCommon Stock	2,139	$0.00	$0.00	Disclosure SEC source: 0001209191-22-025451 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document
March 03, 2022 Filed Mar 7, 2022 23:42 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $68.22	$0.00	Disclosure SEC source: 0001062993-22-007003 · form4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-03-03 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	41	$569.54	$23,351.07	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 8 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,597 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $568.675 to $569.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	2	$567.35	$1,134.71	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 7 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,638 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $567.295 to $567.41. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	87	$565.51	$49,199.61	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 6 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,640 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $565.13 to $565.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	65	$564.24	$36,675.46	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,727 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $563.83 to $564.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	116	$562.79	$65,283.44	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,792 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $562.48 to $563.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	78	$561.85	$43,824.35	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,908 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $561.31 to $561.925. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	70	$558.78	$39,114.64	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,986 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $558.40 to $559.14. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:53 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	41	$556.89	$22,832.49	Disclosure SEC source: 0001093557-21-000270 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,056 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	40	$634.01	$25,360.40	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 11 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,097 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	40	$631.26	$25,250.40	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 10 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,137 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	42	$629.33	$26,431.86	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 9 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,177 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	76	$628.41	$47,758.96	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 8 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,219 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $628.24 to $628.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	56	$627.79	$35,156.50	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 7 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,295 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $627.045 to $627.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	7	$626.05	$4,382.32	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 6 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,351 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	124	$625.32	$77,539.52	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,358 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $624.96 to $625.75. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	43	$624.10	$26,836.17	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,482 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $623.955 to $624.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	13	$622.63	$8,094.13	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,525 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	14	$619.32	$8,670.48	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,538 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:13 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	45	$615.13	$27,680.85	Disclosure SEC source: 0001093557-21-000251 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,552 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	1	$551.58	$551.58	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 7 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,597 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	51	$547.06	$27,900.00	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 6 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,598 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $547.00 to $547.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	181	$544.39	$98,535.13	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,649 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $544.07 to $544.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	126	$543.15	$68,436.61	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,830 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $542.79 to $543.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	88	$540.93	$47,601.84	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,956 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	6	$539.10	$3,234.60	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,044 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 01, 2021 Filed Oct 5, 2021 22:28 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	47	$538.02	$25,286.94	Disclosure SEC source: 0001093557-21-000235 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,050 F1 · shares: On June 15, 2021, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
June 11, 2021 Filed Jun 15, 2021 19:24 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	SaleCommon Stock	2,500	$95.02	$237,540.00	Disclosure SEC source: 0001209191-21-040544 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,276 F1 · price: The price reported in this row represents a weighted average price of $95.017 per share. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.091, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F2 · balance_after: The number of shares reflected in this column does not include 24,597 vested RSUs that the Reporting Person elected to defer at the time of grant until his retirement from the Board of Directors. Read SEC document
May 21, 2021 Filed May 25, 2021 23:16 UTC	DEXCOM INC DXCM · Entity 3114	GrantCommon Stock	1,054	$0.00	$1.05	Disclosure SEC source: 0001093557-21-000138 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054 F2 · shares: The RSU Award was granted on May 21, 2021 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 1,054 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. Read SEC document
May 20, 2021 Filed May 25, 2021 23:16 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	895	$0.00	$0.00	Disclosure SEC source: 0001093557-21-000138 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,097 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. F4 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
May 20, 2021 Filed May 25, 2021 23:16 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	895	$0.00	$0.00	Disclosure SEC source: 0001093557-21-000138 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document
April 21, 2021 Filed Apr 23, 2021 18:53 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	GrantRestricted Stock Units · Derivative	2,139	$0.00	$0.00	Disclosure SEC source: 0001209191-21-028083 · doc4.xml · derivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,139 Underlying: Common Stock · 2,139 shares Expires not disclosed F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F5 · derivative.exercise_date: The RSUs identified in this row were granted on April 21, 2021 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2022. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 21, 2021 Filed Apr 23, 2021 18:53 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionRestricted Stock Units · Derivative	2,826	$0.00	$0.00	Disclosure SEC source: 0001209191-21-028083 · doc4.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,826 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F3 · derivative.exercise_date: The RSUs identified in this row were granted on April 22, 2020 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2021. Accordingly, the number of RSUs identified in this row vested on April 21, 2021, which was the date of the Company's Annual Meeting of Shareholders in 2021. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 21, 2021 Filed Apr 23, 2021 18:53 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionCommon Stock	2,826	$0.00	$0.00	Disclosure SEC source: 0001209191-21-028083 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document
March 02, 2021 Filed Mar 4, 2021 23:24 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $49.92	$0.00	Disclosure SEC source: 0001177648-21-000013 · edgar.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders. Read SEC document
November 16, 2020 Filed Nov 18, 2020 23:57 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	301	$342.93	$103,221.63	Disclosure SEC source: 0001093557-20-000306 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,202 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $342.53 to $343.185. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 16, 2020 Filed Nov 18, 2020 23:57 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	428	$341.79	$146,284.41	Disclosure SEC source: 0001093557-20-000306 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,503 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $341.37 to $342.295. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 16, 2020 Filed Nov 18, 2020 23:57 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	117	$340.23	$39,807.37	Disclosure SEC source: 0001093557-20-000306 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,931 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $339.93 to $340.565. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 16, 2020 Filed Nov 18, 2020 23:57 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	139	$337.78	$46,951.42	Disclosure SEC source: 0001093557-20-000306 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,048 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
November 16, 2020 Filed Nov 18, 2020 23:57 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	15	$336.98	$5,054.71	Disclosure SEC source: 0001093557-20-000306 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,187 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $336.40 to $337.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:30 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	208	$398.25	$82,835.42	Disclosure SEC source: 0001093557-20-000284 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,202 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $398.00 to $398.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:30 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	375	$397.41	$149,030.10	Disclosure SEC source: 0001093557-20-000284 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,410 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $397.005 to $397.885. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:30 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	255	$396.51	$101,109.16	Disclosure SEC source: 0001093557-20-000284 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,785 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $395.93 to $396.715. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:30 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	120	$395.02	$47,402.40	Disclosure SEC source: 0001093557-20-000284 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,040 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $394.665 to $395.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:30 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	42	$391.48	$16,442.34	Disclosure SEC source: 0001093557-20-000284 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,160 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $391.07 to $391.505. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.